,,iii #aagth ,,congress #b;d ,session ,s4 ,,res4 #ggb ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,september #ai1 #bjbb,mr4 ,kaine 7for himself1 ,ms4 ,lummis1 ,ms4 ,klobuchar1 and ,ms4 ,smith7 submitted the following resolution2 which was referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,,resolution ,recognizing the seriousness of myotonic dystrophy and expressing support for the designation of ,september #ae1 #bjbb1 as ,international ,myotonic ,dystrophy ,awareness ,day4 ,whereas myotonic dystrophy is a rare1 multi-systemic1 inherited disease that affects approximately #a in #b1ajj individuals and more than #aej1jjj individuals in the ,united ,states2 ,whereas #a in #h1jjj individuals are living with myotonic dystrophy globally1 yet thousands of individuals do not know they have the disease and are in need of care2 ,whereas myotonic dystrophy is the most common form of adult-onset muscular dystrophy1 and the symptoms of the disease become more severe with each generation2 ,whereas the disease is caused by a mutation in the ,,dmpk gene1 resulting in myotonic dystrophy type #a1 or the ,,cnbp gene1 resulting in myotonic dystrophy type #b2 ,whereas those mutations prevent those genes from functioning properly1 impacting multiple body systems2 ,whereas those mutations are autosomal dominant mutations1 in which one copy of the altered gene is sufficient to cause the disorder1 and affected individuals have a #ej percent chance of passing on the mutated gene to their children2 ,whereas1 through this inherited genetic anomaly1 individuals with myotonic dystrophy experience varied and complex symptoms1 ranging from skeletal muscle problems1 early cataracts1 and excessive daytime sleepiness to heart1 breathing1 digestive1 hormonal1 speech1 swallowing1 diabetic1 immune1 vision1 and cognitive difficulties2 ,whereas myotonic dystrophy is a highly variable and complicated disorder1 and the younger an individual is when symptoms first appear1 the more severe symptoms are likely to be2 ,whereas misdiagnoses have persisted for decades1 and delays in diagnosing myotonic dystrophy are common2 ,whereas there are currently no treatments approved by the ,food and ,drug ,administration for myotonic dystrophy2 ,whereas the ,myotonic ,dystrophy ,foundation was founded in #bjjg with a mission to enhance the quality of life of individuals living with myotonic dystrophy and accelerate research focused on finding treatments and a cure2 ,whereas1 in #bjad1 ,congress enacted the ,paul ,d4 ,wellstone ,muscular ,dystrophy ,community ,assistance1 ,research and ,education ,amendments of #bjad 7,public ,law #aac-aff2 #abh ,stat4 #ahgi71 which advanced muscular dystrophy research and public health surveillance activities1 including for myotonic dystrophy2 ,whereas1 in ,september #bjag1 recognizing the seriousness of the disease and the especially disabling impact of myotonic dystrophy on individuals with congenital myotonic dystrophy1 the ,social ,security ,administration added congenital myotonic dystrophy to the ,compassionate ,allowance ,program1 which allows individuals to quickly qualify for disability benefits1 including health insurance coverage2 ,whereas1 in #bjah1 ,congress added myotonic dystrophy to the list of eligible conditions for research funding under the ,peer ,reviewed ,medical ,research ,program of the ,department of ,defense1 which resulted in more than #f1jjj1jjj in new research awards2 and ,whereas a more robust scientific investment in myotonic dystrophy research will improve health outcomes1 reduce disability1 and increase life expectancy for individuals living with myotonic dystrophy1 and holds great promise for helping individuals with similar genetic diseases3 ,now1 therefore1 be it ,that the ,senate-- 7#a7 expresses support for the designation of ,september #ae1 #bjbb1 as ,international ,myotonic ,dystrophy ,awareness ,day2 7#b7 recognizes the seriousness of myotonic dystrophy2 and 7#c7 supports the goals and ideals of ,international ,myotonic ,dystrophy ,awareness ,day1 which include-- 7,a7 committing to promoting and advancing the health1 well-being1 and inherent dignity of all children and adults with myotonic dystrophy2 7,b7 supporting the advancement of scientific and medical myotonic dystrophy research2 7,c7 fostering biopharmaceutical innovation that will lead to ,food and ,drug ,administration-approved treatments and eventually a cure for myotonic dystrophy2 7,d7 advancing programs and policies that assist individuals living with myotonic dystrophy and the caregivers of such individuals2 and 7,e7 encouraging awareness and education of myotonic dystrophy for patients1 caregivers1 clinicians1 and researchers4